聯邦制藥(03933.HK):德谷門冬雙胰島素注射液臨牀註冊申請獲受理
格隆匯4月26日丨聯邦制藥(03933.HK)發佈公吿,2022年4月15日,公司全資附屬公司聯邦生物公司接獲國家藥品監督管理局關於德谷門冬雙胰島素注射液臨牀註冊申請受理通知書,受理號為CXSL2200172。
根據披露,德谷門冬雙胰島素由新一代超長效基礎胰島素類似物聯合餐時胰島素類似物組成,含70%德谷胰島素及30%門冬胰島素。兩種組分以獨立、穩定的可溶性形式存在,且不改變各自組分的藥理學性質,可同時控制空腹及餐後血糖。相比於目前臨牀使用的預混胰島素類似物,德谷門冬雙胰島素能更好地模擬生理性胰島素分泌模式,降糖治療更安全、有效,為糖尿病患者實現全面血糖控制提供了更為理想的選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.